DexCom's issues predate the recent market volatility. The company did not perform well last year as its financial results disappointed investors. The stock dropped 37% through 2024. DexCom is down ...

A stock is considered to be oversold if the RSI reading falls below 30. In trading on Friday, shares of DexCom Inc (Symbol: DXCM) entered into oversold territory, hitting an RSI reading of 29.6 ...

DexCom Inc. closed 51.77% below its 52-week high of $142.00, which the company achieved on March 26th.

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

Investors with a lot of money to spend have taken a bullish stance on DexCom DXCM. And retail traders should know. We noticed this today when the positions showed up on publicly available options ...

DexCom's growth is slowing, with 2024 marking the slowest growth year in a decade and 2025 expected to follow suit with ~14% growth. Intensifying competition from Abbott and Medtronic and the rise ...

In this article, we are going to take a look at where DexCom, Inc. (NASDAQ:DXCM) stands against other best growth stocks under $100 to buy now. Growth stocks are shares of companies which are ...

Dexcom stock plunged to a four-month low Monday after the Food and Drug Administration issued the diabetes devices maker a ...

Shares of DexCom Inc. DXCM shed 2.68% to $88.32 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average DJIA rising 0.37% to ...

Dexcom is still expected to hit 2025 revenue despite the diabetes device giant receiving a warning from the US Food and Drug Administration (FDA) after site inspections, according to market analysts.